Por favor, use este identificador para citar o enlazar este ítem: https://repositorio.usj.es/handle/123456789/379

Registro completo de metadatos
Campo DC Valor Lengua/Idioma
dc.contributor.authorCarpéné, Christian-
dc.contributor.authorLes, Francisco-
dc.contributor.authorMercader, Josep-
dc.contributor.authorGómez-Zorita, Saioa-
dc.contributor.authorGrolleau, Jean Louis-
dc.contributor.authorBoulet, Nathalie-
dc.contributor.authorFontaine, Jessica-
dc.contributor.authorIglesias-Osma, Maria Carmen-
dc.contributor.authorGarcia-Barrado, Maria José G.-
dc.date.accessioned2020-04-28T09:17:27Z-
dc.date.available2020-04-28T09:17:27Z-
dc.date.issued2020-03-05-
dc.identifier.citationCarpéné, C., Les, F., Mercader, J., Gomez‐zorita, S., Grolleau, J. -., Boulet, N., . . . Garcia‐barrado, M. J. (2020). Opipramol inhibits lipolysis in human adipocytes without altering glucose uptake and differently from antipsychotic and antidepressant drugs with adverse effects on body weight control. Pharmaceuticals, 13(3) doi:10.3390/ph13030041es_ES
dc.identifier.issn1424-8247es_ES
dc.identifier.urihttps://repositorio.usj.es/handle/123456789/379-
dc.descriptionTreatment with several antipsychotic drugs exhibits a tendency to induce weight gainand diabetic complications. The proposed mechanisms by which the atypical antipsychotic drugolanzapine increases body weight include central dysregulations leading to hyperphagia anddirect peripheral impairment of fat cell lipolysis. Several investigations have reproducedin vitrodirect actions of antipsychotics on rodent adipocytes, cultured preadipocytes, or human adiposetissue-derived stem cells. However, to our knowledge, no such direct action has been describedin human mature adipocytes. The aim of the present study was to compare in human adipocytesthe putative direct alterations of lipolysis by antipsychotics (haloperidol, olanzapine, ziprazidone,risperidone), antidepressants (pargyline, phenelzine), or anxiolytics (opipramol). Lipolytic responsesto the tested drugs, and to recognized lipolytic (e.g., isoprenaline) or antilipolytic agents (e.g.,insulin) were determined, together with glucose transport and amine oxidase activities in abdominalsubcutaneous adipocytes from individuals undergoing plastic surgery. None of the tested drugswere lipolytic. Surprisingly, only opipramol exhibited substantial antilipolytic properties in themicromolar to millimolar range. An opipramol antilipolytic effect was evident against isoprenaline-,forskolin-, or atrial natriuretic peptide-stimulated lipolysis. Opipramol did not impair insulinactivation of glucose transport but inhibited monoamine oxidase (MAO) activity to the same extentas antidepressants recognized as MAO inhibitors (pargyline, harmine, or phenelzine), whereasantipsychotics were inefficient. Considering its unique properties, opipramol, which is not associated with weight gain in treated patients, is a good candidate for drug repurposing because it limitsexaggerated lipolysis, prevents hydrogen peroxide release by amine oxidases in adipocytes, and isthereby of potential use to limit lipotoxicity and oxidative stress, two deleterious complications ofdiabetes and obesity.es_ES
dc.format.extent19 p.es_ES
dc.format.mimetypeapplication/pdfes_ES
dc.language.isoenges_ES
dc.publisherMDPI AGes_ES
dc.relationFunding: This research received no external grants. Corresponding authors’ studies were supported by recurrent funding from the French National Institute of Health (INSERM), whereas other authors were supported by Paul Sabatier, San Jorge, Islas Baleares, Pais Vasco, and Salamanca Universities.es_ES
dc.rightsAtribución 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.subjectTejido adiposoes_ES
dc.subjectObesidades_ES
dc.subjectMonoamina oxidasaes_ES
dc.subjectAmina oxidasa sensible a semicarbazidaes_ES
dc.subjectTransporte de glucosaes_ES
dc.subjectLipotoxicidades_ES
dc.subjectInsulinaes_ES
dc.subjectAntidepresivo antipsicótico harmina fenelzinaes_ES
dc.subjectOpipramoles_ES
dc.titleOpipramol inhibits lipolysis in human adipocytes without altering glucose uptake and differently from antipsychotic and antidepressant drugs with adverse effects on body weight controles_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.subject.unescoObesidades_ES
dc.identifier.doi10.3390/ph13030041es_ES
dc.rights.accessrightsinfo:eu-repo/semantics/openAccesses_ES
Aparece en las colecciones: Artículos de revistas

Ficheros en este ítem:
Fichero Descripción Tamaño Formato  
Opipramol inhibits lipolysis in human adipocytes without altering glucose uptake and differently from antipsychotic and antidepressant drugs with adverse effects on body weight control.pdf2,05 MBAdobe PDFVista previa
Visualizar/Abrir
Mostrar el registro sencillo del ítem


Este ítem está sujeto a una licencia Creative Commons Licencia Creative Commons Creative Commons